EARLY-ONSET LEUKOPENIA AND SEVERE THROMBOCYTOPENIA FOLLOWING DOXORUBICIN CHEMOTHERAPY FOR TONSILLAR SQUAMOUS-CELL CARCINOMA IN A DOG

被引：0
|
作者：
HENRY, CJ
BREWER, WG
STUTLER, SA
机构：
来源：
CORNELL VETERINARIAN | 1993年 / 83卷 / 02期
关键词：
DOG; DOXORUBICIN; LEUKOPENIA; MYELOSUPPRESSION; THROMBOCYTOPENIA;
D O I：
暂无
中图分类号：
S85 [动物医学（兽医学）];
学科分类号：
0906 ;
摘要：
Doxorubicin is reported to cause myelosuppression, with a white blood cell count nadir occurring between day 7 and day 10. Thrombocytopenia is less severe and occurs between days 3 and 8. This report presents an early onset of leukopenia (day 5) and a severe thrombocytopenia (4000 platelets/microliter) (day 6) associated with doxorubicin administration for treatment of recurrent tonsillar squamous cell carcinoma in a dog.
引用
收藏
页码：163 / 168
页数：6
相关论文
共 22 条
  • [21] Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma
    Abgral, Ronan
    Le Roux, Pierre-Yves
    Keromnes, Nathalie
    Rousset, Jean
    Valette, Gerald
    Gouders, Dominique
    Leleu, Cyril
    Mollon, Delphine
    Nowak, Emmanuel
    Querellou, Solene
    Salauen, Pierre-Yves
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (12) : 1839 - 1847
  • [22] Detection of alteration in carotid artery volumetry using standard-of-care computed tomography surveillance scans following unilateral radiation therapy for early-stage tonsillar squamous cell carcinoma survivors: a cross-sectional internally-matched carotid isodose analysis
    Koutroumpakis, Efstratios
    Naser, Mohamed A.
    Mohamed, Abdallah Sherif Radwan
    Eraj, Salman A.
    Jarre, Andrea
    Shiao, Jay C.
    Kamal, Mona
    Perni, Subha
    Phan, Jack P.
    Morrison, William H.
    Frank, Steven J.
    Gunn, G. Brandon
    Garden, Adam S.
    Deswal, Anita
    Abe, Jun-ichi
    Rosenthal, David I.
    Mouhayar, Elie
    Fuller, Clifton D.
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2025, 51
123